Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease

Watkins, Paul B. · 1994 · JAMA: The Journal of the American Medical Association

Abstract

OBJECTIVE: To characterize the hepatic effects of tacrine treatment in patients with Alzheimer's disease. DESIGN: Controlled trials of tacrine therapy consisting of two blinded, parallel-group trials; three blinded, enrichment-design trials; and their respective open-label extensions. SETTING: Multicenter clinical trials in the United States, France, and Canada. PATIENTS: A total of 2446 men and women at least 50 years of age with a diagnosis of probable Alzheimer's disease of mild to moderate severity and in good health without significant hepatic, cardiovascular, or renal disease. INTERVENTION: Administration of tacrine vs placebo, with weekly measurement of serum hepatic enzymes. MAIN OUTCOME MEASURES: Incidence, maximum severity, and timing of event for serum alanine aminotransferase (ALT) elevation. RESULTS: Among the 2446 patients who received tacrine in clinical trials, ALT levels greater than the upper limit of normal (ULN) occurred on at least one occasion in 1203 patients (49%), ALT levels greater than three times the ULN occurred in 621 patients (25%), and ALT levels greater than 20 times the ULN occurred in 40 patients (2%). The elevated ALT levels were generally asymptomatic and occurred more frequently in women than men. The mean time from initiation of tacrine treatment to first ALT level greater than three times the ULN was 50 days, and 90% of all initial ALT levels greater than three times the ULN occurred during the first 12 weeks of treatment. Of 145 patients who discontinued tacrine treatment because of an ALT level greater than three times the ULN and were rechallenged, 127 (88%) were able to resume long-term therapy with the drug. In all instances, discontinuing tacrine completely reversed elevations in ALT levels, and no deaths related to hepatotoxicity occurred. CONCLUSIONS: These data suggest that the potential for serious hepatic toxicity can be reduced through careful monitoring of ALT levels in patients who may benefit from tacrine therapy.

Overview

Integrity signals

Registry

Crossref · 10.1001/jama.1994.03510370044030

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 18 references

Cited by

See all 873

Metadata

Authors
Watkins, P. B.
Affiliations
University of Michigan (US)
Corresponding author
Watkins, Paul B.
Venue
JAMA: The Journal of the American Medical Association
Published
1994-04-06
Volume
271
Issue
13
Pages
992
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2000837493
Cited by
829
References
18
Citations by year
2026: 29 · 2025: 26 · 2024: 28 · 2023: 28 · 2022: 34 · 2021: 32 · 2020: 37 · 2019: 37 · 2018: 24 · 2017: 33 · 2016: 30 · 2015: 31 · 2014: 36 · 2013: 29 · 2012: 27
FWCI
29.19
Type
journal article
Language
en
Open access
closed
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
tacrine, Alzheimer's disease, hepatotoxicity, alanine aminotransferase elevation, drug-induced liver injury, liver enzymes, drug safety, sex differences in drug response
MeSH terms
Aged, Alanine Transaminase, Alzheimer Disease, Drug Administration Schedule, Female, Humans, Liver Diseases, Male, Middle Aged, Risk Factors, Tacrine, Drug Monitoring, Chemical and Drug Induced Liver Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease. https://app.cochat.ai/papers/10.1001/jama.1994.03510370044030
The paper
Watkins, P. B. (1994). Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease. JAMA: The Journal of the American Medical Association. https://doi.org/10.1001/jama.1994.03510370044030

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.